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Abstract 
A microfluidic system was developed for blood plasma separation at high flow rate. This system uses 
only hydrodynamic forces to separate red and white blood cells from whole blood. The microfluidic 
network features a series of constrictions and bifurcations to enhance the product yield and purity. A 
maximum purity efficiency of 100% is obtained on blood with entrance hematocrit level up to 30% 
with a flow rate of 2mL/hr. Flow cytometry was performed on the extracted plasma to evaluate the 
separation efficiency and to assess cell damage. A core target of this study was the detection of cell-
free DNA from the on-chip extracted plasma. To this effect, PCR was successfully carried out off-
chip on the cell-free DNA present in the plasma extracted on chip. The cell-free DNA was amplified 
without the need for purification after the separation, thereby showing the high quality of the plasma 
sample. The resulting data suggests that the system can be used as a preliminary module of a total 
analysis system for cell free DNA detection in human plasma. 
 
Introduction 
Blood Plasma separation on-chip 
Optimum on-chip blood plasma separation techniques should have a high plasma yield, a large 
throughput and a high plasma purity, while keeping cellular damage to a minimum, such as not to 
contaminate the plasma with cellular DNA. On one hand, the miniaturization of centrifugation has 
been the topic of many research groups. Ducrée and Madou, for example, have utilised centrifugal 
forces developed through the rotation of their lab-on-CD devices to separate red blood cells from 
plasma
1,2
. On the other hand, other researchers have focused on the development of a continuous 
separation method applicable to blood plasma separation. Jang et al developed a microfluidic network 
with a series of bifurcations ranging between 10 and 20μm in width. Faivre has used constrictions 
integrated before the bifurcation to increase the natural cell-free layer of blood flow at low Reynolds 
number
3
. Recently, Rodríguez-Villarreal et al. have demonstrated a high flow rate blood plasma 
separation device using one constriction and one bifurcation
4
. The biological validation of the 
resulting extracted plasma in terms of contamination was not however presented in this article. 
In this paper we present a blood plasma extraction microsystem based on multiple constrictions in a 
microfluidic network together with the biological validation of this device through the detection of 
human cell free DNA (cfDNA) in the extracted plasma
5
. The chip overcomes certain limitations 
encountered in the literature as it runs at high-flow rate, high throughput, obtains a high level of 
plasma purity while causing very little cellular damage allowing thereby the extracted plasma to be 
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suitable for detection of cfDNA. In this regard, our microfluidic plasma separator can be regarded as a 
preliminary module to a low cost total analysis system for these types of applications
6
. 
 
cfDNA 
The existence of cell free DNA (cfDNA) in human plasma was first detected in cancer patients over 
30 years ago
7
.However only in the last few years has its true diagnostic potential been realised 
resulting in an increasing interest in the detection and analysis of cfDNA
8,9,10,11
. Potential applications 
of cfDNA detection include the diagnosis and prognosis of various malignancies
8,9,11,12
, the 
monitoring of graft versus host disease after organ transplantation
13
 and non invasive prenatal 
diagnosis (NIPD)
14
. For the latter, cell free 75 foetal DNA, cffDNA, is not only used today to 
diagnose gender-linked conditions
15
 or foetal rhesus D status
16,17 
but cffDNA is also employed as an 
indicator for pregnancy associated diseases such as pre-eclampsia and preterm labour
18
. 
 
Analysis of cfDNA from plasma by PCR 
Analysis of cfDNA first requires the separation of plasma or serum from whole blood. Purification is 
mostly required to remove the major inhibitors of the Polymerase Chain Reaction (PCR). These 
include natural components such as heme and immunoglobulin G and exogenous components such as 
anticoagulants
28
. Furthermore, the plasma must be completely free of cells, reducing thereby the 
contamination of the plasma with cellular DNA which can interfere with the accuracy of the DNA 
analysis. Traditionally plasma is separated from blood by centrifugation or filtration. For the 
preparation of cfDNA an additional step of filtration or micro-centrifugation is often recommended to 
ensure that the plasma or serum is of a high purity
29
. The DNA may be further purified by extraction 
before performing PCR. As yet there are no officially agreed standards for the purification of DNA 
from plasma, but the most common and fastest method is the QIAamp blood kit, which uses the 
binding of DNA to a silica gel membrane. Some studies claim however a 20% less recovery of 
cfDNA using this kit compared to other methods of DNA purification such as the Triton/Heat/Phenol 
(THP) protocol
30
. 
CfDNA loss during purification has been reported to occur due to the small fragment size
31
. These 
processing steps although necessary can also be slow and cumbersome. Moreover the generation of 
aerosols is common during centrifugation, which can be a potential risk of infection and 
contamination. Cell damage and cell loss is also a concern during centrifugation
32
. For point-of-care 
diagnostics, it is also well known that sample preparation step is a serious bottleneck in microfluidics. 
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The development of a miniaturised module capable of de-skilled blood separation would aid in the 
translation of this new technology. 
The objective of this study was to investigate: (i) the influence of the entrance hematocrit and flow 
rate on the separation efficiency, (ii) the hematocrit and the cell-free zones, (iii) the purity of the 
plasma obtained using flow cytometry, (iv) the influence of the dilution of whole blood prior to on-
chip separation and (v) the influence of the separation efficiency on the PCR efficiency. In order to 
prove the presence of biomarkers in the extracted plasma and to study the detection limits versus 
dilution levels and purity efficiency, we also performed a series of PCR reactions on human genes. 
 
Theory and Design of a Blood Plasma Separator 
The number of parameters affecting the flow of cells in a microchannel renders difficult the prediction 
of separation system behaviour. An earlier publication has discussed in details the presence and 
effects of viscous and inertial lift forces which enable particles to be separated at the microscale
5
. In a 
straight microchannel, deformable particles such as leukocytes move away from the walls under either 
the effect of inertial lift if the Reynolds number is close to 1 or by viscous lift when the Reynolds 
number is low. Both effects arise from the presence of a stationary wall and the interaction of a shear 
gradient on the particle. A transitional regime also exists where both effects may co-exist as discussed 
in
5,33
. The cell-free layer observed on the walls at certain conditions depends also on the particle-
particle interactions and the particle concentration. The design presented here exploits two main 
hydrodynamic effects: the Zweifach-Fung bifurcation law and the blood flow focusing effect 
occurring after a constriction. The Zweifach-Fung bifurcation law is an empirical law that addresses 
the deformable particle behaviour at a bifurcation
34
. At a bifurcation, a cell will have the tendency to 
travel to the daughter channel with the highest flow rate, providing that the cell dimension is 
comparable to the channel dimension. Although this law was first stated in the context of micro 
circulation in the human body, it has also been exploited for in-vitro separation
35
. From a few cells in 
a microvessel, the law was generalised to accommodate the situation where populations of cells flow 
in microchannels several tens of microns wide. The Zweifach-Fung effect is commonly used in the 
design of micro-separators to set up a lower limit for flow rate ratio at a bifurcation. However, the 
physics which underpin the law and its limitations are not clearly understood yet. The second effect is 
the focusing of the flow of red blood cells after a constriction. In 
5
 the cell free layer of blood and the 
focusing of red blood cells after constriction were found to be small in a the 200μm wide 
microchannel. Faivre et al., reported better focus but used lower Reynolds number and therefore lower 
flow rate even at higher viscosity
3
. In this study we chose to keep the entrance flow rate high, and use 
inertial lift forces rather than viscous ones. 
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As shown in Figure 1, the design bears four connections, a single inlet for whole blood, one outlet for 
the concentrated cells and two outlets for the extracted plasma. Four plasma channels of 5.5mm in 
length are placed on each side of a 100μm wide main channel at a 45º angle. Meanders are used to 
minimize the area occupied by the eight plasma channels and keep the footprint of the chip low. A 
constriction has been placed before each of the plasma channels in order to create a cell-free zone 
from which the plasma is extracted. A set of chips has 20μm wide plasma channels while another has 
10μm wide plasma channels. The depth of the microchannel networks is 20μm for all structures. 
 
 
Figure 1. Schematic of a 20μm wide microchannel blood plasma separator. The flow of plasma is 
indicated by the yellow arrows. 
 
The plasma channels due to their geometrical features (length and width) have a high fluidic 
resistance value, whereas the main channel segment which has broader width and shorter length has 
lower resistance; this difference in resistance value at each bifurcation is proportional to the flow rate 
ratio. The value of the fluidic resistance of the main channel decreases after each bifurcation. Since 
the plasma channels have the same lengths the flow rate ratios are expected to be different at each 
bifurcation. The flow rate ratios can be roughly calculated by the Saber(TM) Microfluidic 
applications software (CoventorWare). Flow rate ratios have been calculated as approximately 17.8, 
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22.6, 31.8 and 55.6 for the left hand side of the chip (bifurcations 1, 3, 5, 7) and 19.2, 25.7, 40.1, and 
94.5 for the right hand side of the chip (bifurcations 2, 4, 6, 8) with 20μm plasma channels. The side 
having the highest flow rate ratios is expected to perform better. Theoretically, the design should 
extract 30% of plasma for the 20μm design and 7% for the 10μm design. 
 
Materials and methods 
Microfluidic chip manufacturing 
The microfluidic chips were manufactured by our industrial collaborator, Epigem Ltd (Redcar, UK). 
The chips consist of several sandwiched layers of the negative photoresist, SU8 between two PMMA 
layers, ensuring a “whole SU8” channel network. SU8 is patterned using conventional 
photolithography. Since the chip footprint is small (18mm x 23mm) a generic platform also made 
from an assembly of PMMA and SU8 is used as a holder featuring standard microfluidic connections 
(Cheminert) as shown in Figure 2. 
 
 
 
← Figure 2. Photo of 
experimental set-up (1) Syringe 
pump and 1mL syringe loaded 
with blood. (2) Blood plasma 
separation chip device loaded 
with chip. Eppendorfs on the left 
collect blood cells, while 
eppendorfs on the right collect 
plasma (3) USB 5 Microscope (4) 
Laptop for visualisation. 
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Samples 
Human blood was obtained in 500mL bags from the Scottish National Blood Transfusion Service, 
Lauriston Place, Edinburgh. Samples were used with the donors’ prior consent and ethical clearance 
was obtained from the SNBTS Sample Governance Committee. Blood was treated with oxalate and 
stored at 4°C upon the day of reception. The blood was used within a month. Ideally the blood should 
be separated on the same day, and the PCR performed within hours after the separation. However, this 
could not be achieved in the current situation. This delay has been taken into account when 
interpreting the results. During the length of the study two different blood samples were obtained. The 
blood samples were subjected to different dilutions using Phosphate Buffered Saline, (PBS, Sigma). 
The dilution levels ranged from zero to 1:20. Dilution levels on different blood samples are biased by 
the intrinsic hematocrit of the blood donor at the time of the collection. Therefore, only resulting 
hematocrit levels truly reflect the different dilutions performed. Hematocrit level measurements and a 
full cell count were performed using a Beckmann Coulter Counter before each run. 
 
Experimental set-up 
The tests were performed at the Division of Pathway Medicine (DPM), University of Edinburgh 
(Royal Infirmary of Edinburgh, Little France, Edinburgh) in a level II biosafety facility. The chip was 
loaded onto the holder with microfluidic connections. The chip and holder assembly was placed onto 
a custom made back-light apparatus and examined under a digital microscope (DinoLite USB 
microscope, Big C, USA) to observe the flow and detect any obstacle to the flow path during each 
experiment. The flow was activated at flow rates ranging from 1mL/h to 10mL/hr (from 16.7μL/min 
to 167μL/min) by a syringe pump (Aladdin, WPI, USA). A syringe of 1mL (BD Plastipak) of blood 
was loaded for each experiment. 
 
Microfluidic blood plasma separation 
Around 50μL aliquots of each blood samples were placed in individual eppendorf tubes for hematocrit 
level verification using a Beckmann Coulter Counter. The microfluidic devices were prefilled before 
each experiment with a 1% BSA-PBS buffer for at least 10 minutes to avoid cell adhesion during the 
separation process
3
. Despite this prevention, the microfluidic network tends to clog up after at least 
three experiments due to platelets aggregations. If a blockage was spotted, or if the efficiency of the 
chip seemed to drop, the chip was discarded and a new one was loaded on the holder. The chips are 
meant to be low cost and disposable and should really be single-use. Once the blood samples filled the 
main channel, the separation process occurred at each bifurcation and the plasma flowed through the 
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individual plasma channels and collection channel. The cell enriched mixture and the extracted 
plasma were collected in three individual eppendorf tubes, as shown in Figure 2, and stored at 4°C 
until further processing. 
 
Results 
Separation efficiency 
Influence of the entrance hematocrit and flow rate on the separation efficiency 
The influence of entrance hematocrit on the separation efficiency was studied using different dilution 
levels. For the chip with the 20μm plasma channels, the corresponding hematocrit levels to the 
dilution levels were comprised between 3.3% and 31%. In the chip with the 10μm plasma channels, 
higher levels of hematocrit were studied, ranging from 9.4% to 45%. The purity efficiency was 
defined as: 
 
Ep =  1− 
 
Where cp and cf are the number of Red Blood Cells (RBCs) per mL in the plasma collection outlet and 
in the feed inlet, respectively. 
Figure 4 shows the different purity efficiencies obtained as a function of the entrance hematocrit 
levels in the 20μm plasma channel microfluidic chip. Some hematocrit levels have several 
experimental points (two or four). Two points are due to the independent measurement of data from 
each plasma outlet. Four points are due to two different experiments, each of them having two 
different experimental points from each of the plasma outlets. Three different flow rates were used 
(2mL/h, 5mL/h and 10mL/h), hence figure 4 also measures the influence of flow rate on the 
separation efficiencies. At entrance hematocrit (eHCT) levels of 1.8% to 10%, the efficiency of the 
first plasma branch is comprised between 95% and 100%. For an entrance hematocrit greater than 
10% the purity efficiency decreases regularly from approximately 95% to 32% for an eHCT of 33.7%. 
Hemoglobin levels recorded by the Cell Counter Coulter are also indicated here to report on the 
damage of the RBCs. The hemoglobin level can reach 100g/L for sample of eHCT of 33.7% 
processed at 5mL/hr. Below eHCT of 15% the hemoglobin level is below 20g/L. The total yield 
obtained by the 20μm wide channel design was approximately 30%. 
cp 
cf 
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Figure 4. Influence of the hematocrit level on the purity efficiency and cell lysis in the 20μm wide 
plasma channels model at different blood flow rates. 
 
Figure 5 details the results of the 10μm plasma channel chips. In these experiments the only flow rate 
used was 2mL/h. Again hemoglobin levels are indicated here to report on RBC damage. The 
hemoglobin levels are increasing with the hematocrit. However, it stays below the level reported to 
introduce interference with PCR reactions (5g/L)38. The purity efficiency decrease very slightly 
(99%) towards hematocrit levels comparable to whole human blood, with plasma yield reaching 5%. 
(turn to next page →) 
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Figure 5. Influence of the hematocrit level on the purity efficiency and cell lysis in the 10μm wide 
plasma channels model for a flow rate of 2mL/hr. 
 
Hematocrit and the cell-free zones 
The influence of the eHCT on the cell-free zone was observed independently of the flow rate at each 
bifurcation. Figure 6 shows the dependence at bifurcation number 7 (location shown in Figure 1) of 
the cell-free zone on the entrance hematocrit level (eHCT). The lower the entrance hematocrit level, 
the larger is the cell free zone. As illustrated in Figure 6, the cell-free zone can be measured from the 
middle of the construction lateral dimension. From (a) to (b), the hematocrit is divided by 2, while the 
cell-free zone size is multiply by 2.5. For low hematocrit levels (8.3% and 3.3%) and a relatively high 
flow rate (here 10mL/hr) a recirculation pattern forms just after the constriction, while no 
recirculation is observed for a level of 16.8%. The lower the haematocrit level, the larger the 
recirculation pattern will be. The recirculation does not affect the separation efficiency at this flow 
rate, nor does it indicate the presence of turbulence. On the contrary it has been reported that 
recirculation may enhance the separation
39
. 
 
 
Figure 6. Effect of the entrance hematocrit level at bifurcation 7 for a constant flow rate of 10mL/hr, (a) 
eHCT=16.8 (b) eHCT=8.3 (c) eHCT=3.3. The arrow highlights the recirculation flow in (b) and (c). 
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Flow rate and the cell-free zones 
In the same fashion, the influence of the flow rate on the cellfree zones has been observed. Three 
separation experiments were carried out with the same entrance hematocrit of 8.3% and varying flow 
rates of 2mL/h, 5mL/h and 10mL/h. The effect of the flow rate at the third bifurcation is shown in 
figure 7. Compared to the previous example, no recirculation eddies are observed at bifurcation 
number 3. The size of cell free zone here is approximately linear relative to the flow rate. However, 
more data would be needed to establish this linearity. A high flow rate ultimately leads to a higher 
purity but also increases the risk of damaging the cells through greater shear rate forces. 
 
 
Figure 7. Effect of the flow rate at bifurcation 3, for an entrance HCT=8.3% (a) 2mL/hr (b) 5mL/hr 
(c) 10mL/hr. Note: the changes in colour are only due to camera settings at the time of the 
photograph. 
 
Flow cytometric study 
Motivation 
A flow cytometric study was performed on several samples to get an in-depth knowledge of the 
separation of plasma from blood. Flow cytometry allows a very precise counting of particles in a fluid 
and, in this case, provides information on the cell population, such as cell lysis that may be caused by 
the high shear rates in the microchannels. Flow cytometry offers a higher level of sensitivity than can 
be achieved with a Coulter Counter. As the ultimate goal of the plasma separation is to detect cfDNA 
in the plasma, it is crucial to prove that the cells are not damaged/destroyed during separation. 
Damaging the cells and causing lysis leads to more contamination of the plasma. In order to give 
useful biomedical information, the cfDNA detected in the plasma should be present in the blood prior 
to extraction and should not come from cell lysis as a result of sample preparation. 
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Experimental section 
Staining of the blood sample was performed to label leukocytes and platelets. The R-phycoerythrin 
(R-PE)-conjugated monoclonal antibody CD45 (PE Mouse Anti-Human, BD Biosciences) was used 
for leukocytes surface staining. The fluorescein isothiocyanate (FITC)-conjugated CD42 antibodies 
stained the platelets. Using these markers we were able to identify the leukocytes and platelets 
population. The RBCs were identified by being non-stained. Blood cell population analysis was 
carried out on a FACS Scan instrument (BD Biosciences, Franklin Lakes, NJ, USA) and results were 
analysed using Flow Jo software v7.5.3 (Tree Star, Ashland, OR, USA). Determination of 5 the 
absolute cell count was achieved by the use of flow cytometric beads (Flow Count, Beckam). 
 
Results 
Figure 8 shows the results of the flow cytometric data after processing. The horizontal axis represents 
the size of the cells (Forward scatter, FSC) and the vertical axis represents their granularity (Side 
Scatter SSC). In the feed collection the population is mainly constituted of RBCs (95.62%), platelets 
(4.1%), leucocytes (0.28%), which corresponds to normal physiological conditions. Additionally the 
counting beads are present in the mixture, as well as the population identified as platelets aggregates 
and platelets-monocytes aggregates40. The platelets are located in the bottom-left quadrant of the 
diagram, as they are the smallest particles and the least granular. In this quadrant a large population of 
red blood cells is also present; these are either very small RBCs or RBCs debris. The blood sample 
presents a large population of cell debris before any cell separation. A possible explanation for this is 
cell damage caused by the processing, transport and storage of the blood. Other RBCs, counting 
beads, monocytes and platelets aggregates can be found in the upper right quadrant. Linking these two 
quadrants is the “tail” of the healthy RBCs population, smaller or damaged RBCs. Little change is 
observed between the feed collection and the cell collection after separation. The tail does not show 
signs of growth which means that the cells have not been through high stress or have resisted the 
stress. Looking at the plasma collections, the plasma is not entirely devoid of cells, but has been 
strongly depleted by 250 times compared to the feed sample. Most of the RBCs debris has also been 
removed, which enhances the overall quality of the plasma. The population of platelets is the less 
depleted of all cell populations. 
In conclusion, the flow cytometric investigation has shown that the cells are not damaged through the 
system. Additionally, the plasma is not entirely devoid of cells as the cell coulter counter suggests, but 
that the RBC population in the plasma collection has been reduced 250 times compared to the feed 
sample. Finally, the system also removes the cell debris, rendering the plasma even purer. 
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Figure 8. Dot plots of FSC vs. SSC represents the acquisition of 1000 flow check beads in the 250μL 
feed, cell, plasma 1 and plasma 2 collections. Colour correspondence: Dark blue: Flow Check beads, 
Black: leukocytes, Red: platelets, Light Blue: RBCs, Green: monocytes-platelets or platelets 
aggregates. 
 
Detection of biomarkers 
Of interest in this study is the subsequent recovery of cfDNA from the plasma after the on-chip blood 
plasma separation process. To assess the quality of the plasma extracted on-chip, PCR for a house-
keeping gene was performed. The GAPDH gene was chosen for its small molecular weight (200bp) 
Page 13 of 21 
which makes it a challenging target to amplify and also because its size is relative to cfDNA 
fragments
19
. The goal of this biological study is to prove that cfDNA can be amplified and detected in 
plasma obtained using this on-chip separation method. In order to investigate whether the dilution 
level prior to separation alters the recovery of biomarkers we studied the influence of pre-dilution on 
the PCR efficiency. The influence of the separation efficiency on the PCR efficiency has also been 
measured to characterise thelimits of the separation method. 
 
Conventional PCR and gel electrophoresis on house-keeping genetic sequences 
The theoretical aspect of PCR has already been treated in a large body of literature41,42. PCR was 
performed using a Primus 96 thermal cycler. In order to assess the suitability of on-chip blood 
separation as a module in a larger μTAS system with minimal processing steps, no further purification 
was carried out on the plasma prior to PCR. 
 
Amplification of house-keeping gene in the cell-free DNA population present in the plasma 
extracted on-chip 
The amplification primers for the GAPDH gene (Forward primer 5’- GAA GGT GAA GGT CGG 
AGT CA-3’, reverse primer 5’ GAC AAG CTT CCC GTT CTC AG) were purchased from Metabion 
International AG. For the PCR with the GAPDH gene, each reaction aliquot contained 0.4μM forward 
primer, 0.4μM reverse primer, 0.1μM dNTP (Sigma), 80 0.1μM dCTP (Sigma), 2.5U Taq DNA 
polymerase (QIAgen HotStarTaq DNA Polymerase kit), 2.5μL PCR buffer (HotStarTaq DNA 
Polymerase kit), 4mM MgCl2 (QIAgen HotStarTaq DNA Polymerase kit), 9μL DNA free water. For 
each reaction, 5μL of plasma was added to 20μL of the PCR master mix. In order to determine 
whether GAPDH could be amplified directly in whole blood, a control consisting of unpurified blood 
(as received from the blood bank) was measured. As a negative control for PCR, we used ultrapure 
water. Human genomic control DNA was used as a positive control and was obtained from Promega 
in 210ng/uL concentration, diluted 100 times. 1μL of 5 the dilution was added to the 20μL mastermix, 
with 4μL of DNA-free water to get a total of 2ng of DNA per reaction. 
The thermal cycling program consisted of a 10min denaturation at 95°C, followed by 40 cycles of 
1min denaturation at 94°C, 1min primer annealing at 68°C, 1min extension at 72°C. The final 
extension step consisted of a further 5min cycle at 72°C and the samples were kept on hold at 10°C 
until further processing. The PCR product was purified with the QIAgen PCR purification kit using 
the protocol suggested by the manufacturer. The purified DNA product was eluted in 30μL EB buffer. 
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10μL of this product was then loaded onto a 2% agarose gel for analysis by electrophoresis. Gels were 
analysed using a Biorad Gel Doc system. 
 
Influence of the dilution of whole blood previous to on-chip separation 
PCR was performed to detect the GAPDH gene in the plasma samples extracted on-chip. Samples 
were isolated after separation and stored in 1mL eppendorf tubes at 4
o
C prior to use. The separation 
efficiency was characterised by a Coulter Counter as described previously. In order to assess the 
influence of the dilution on the PCR efficiency, six samples with the same separation efficiency but 
different dilution levels (eHCT level varying from 3.3% to 33.7%) were chosen. Achieving the same 
separation efficiency with different pre-diluted samples is possible through the use of the two chip 
models and different flow rates. PCR and gel electrophoresis were performed on these 15 samples, 
following the protocol presented in the previous section. Samples S1 to S6 were duplicated to verify 
the homogeneity of the PCR. Table 1 summarises the different samples and controls used in this first 
experiment. 
  
Separation efficiency of sample (%) Entrance hematocrit level (%) 
Samples S1 100 3.3 
S2 100 6.2 
S3 100 7.0 
S4 100 14.9 
S5 100 17 
S6 100 33.7 
Positive controls G1 Genomic control 1 – 1/10 
G2 Genomic control 2 – 1/100 
G3 Genomic control 3 – 1/1000 
Other controls WB Whole blood 
C Plasma sample extracted by gentle centrifugation (3000 rpm, 10 min) 
Negative control W Ultrapure water 
 
Table 1. Table summarising the characteristics of the samples and controls. 
 
The amplified products of the plasma samples are shown in Figure 9. In all columns except the one of 
the negative control, a clear 200bp band is present, showing the consistent amplification of the 
GAPDH gene fragment. The intensity of the band varies from sample to sample, but the intensity does 
not vary within the duplicates. Both samples in series 1 show a relatively strong amplification band. 
Interestingly, there is a broad trend towards higher fluorescence signal from S1 to S6, (excluding S5) 
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which confirms, as expected, that the resulting concentration achieved by PCR amplification depends 
on the entrance hematocrit of the sample. Additionally, the presence of an amplification band in the 
sample with the highest dilution (corresponding hematocrit level 3.3%) demonstrates that PCR can be 
achieved on strongly diluted samples. All the other controls, including the negative controls show no 
amplification. for the lanes containing the whole blood product (WB), and the plasma extracted by 
centrifugation (C), the PCR has been inhibited, probably by the presence of immunoglobulin G in the 
whole blood and in the plasma sample extracted by centrifugation. To the best of our knowledge, this 
is the first demonstration of PCR on cfDNA in plasma extracted on chip. 
 
 
Figure 9. Ethidium bromide-stained agarose gel of PCR products obtained with GAPDH primer and 
unprepared plasma samples obtained by microfluidic extraction. The first lane is a molecular weight 
marker (1000-bp ladder). 
 
Influence of the separation efficiency on the PCR efficiency 
As demonstrated by Figure 9, PCR can be achieved on cfDNA in plasma extracted on-chip for purity 
efficiency of 100%. Further study was carried out to assess the limits of the PCR capability on cfDNA 
in untreated plasma sample. In that respect, plasma aliquots from samples with similar entrance 
hematocrit levels and with different purity efficiencies were collected after separation and stored at 
4
o
C. The different samples used in this experiment are presented in Table 2. The separation efficiency 
of the samples ranged from 65.1% to 100%. 
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Separation efficiency (%) Hematocrit level (%) 
Plasma samples S1 100 14.9 
S2 97.8 12.3 
S3 94.9 12.3 
S4 84 16 
S5 65.1 16 
Positive controls G1 Genomic control 1 – 1/10 
G2 Genomic control 2 – 1/100 
G3 Genomic control 3 – 1/1000 
Other control WB Whole blood control 
Negative control W Ultrapure water 
 
Table 2. Different samples used in the PCR experiment. 
 
The amplified products of this experiment are shown in ethidium bromide-stained agarose gel in 
Figure 10. A clear gradient of band intensity through samples S1 to S5 can be observed. No PCR 
product could be amplified from S5 which has a purity efficiency of 65.1% and the band from S4 
(84%) is visible but faint. The whole blood and water lanes did not show any amplification. 
 
 
Figure 10. Influence of the separation efficiency on the detection of the GapDH house-keeping gene 
in the on-chip extracted plasma. The first lane is a molecular weight marker (50bp ladder). 
 
This experiment demonstrates that 5 the PCR efficiency depends on the separation efficiency, and 
most importantly shows that at the high separation efficiencies which are standard for our device, 
PCR can be routinely performed. Moreover these experiments successfully showed that the plasma 
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extracted on-chip is pure enough to perform amplification without further purification steps as 
routinely done after centrifugation today, reducing reagent costs, waste and time. It can be noted that 
for more difficult cfDNA targets such as cffDNA, this step might still be necessary. 
One final and important point to consider is the effect of the time delay between draw and processing 
of blood which has been shown to be a factor in the quantification of cfDNA. Lysis of intact cells 
caused by a delay in blood processing would result in increased concentrations of cfDNA (caused by 
ex-vivo processing) which might lead to misleading results especially if cfDNA is used as a 
biomarker in cancer, prenatal and post transplant care. Integrating the process of blood plasma 
separation and PCR analysis onto a single chip would overcome this limitation for the routine use of 
cfDNA analysis in clinical settings. 
 
Conclusions 
This paper demonstrates an efficient and disposable way to extract at high flow rate cell-free plasma 
from whole blood at different dilution levels. The purity efficiency reached 100% even with the use of 
relatively large channels (20μm) suitable for mass manufacturing. PCR was used to demonstrate the 
purity of the extracted plasma without the need for DNA extraction. To the best of our knowledge, we 
describe for the first time the recovery of cell-free DNA from on-chip extracted plasma by PCR and 
gel electrophoresis. As expected, the detection nucleic acids biomarker depends on the separation 
efficiency, but also on the dilution of the blood. Detection was demonstrated in plasma samples with 
purity efficiency from 84% and dilution level up to 1:20. All our findings indicate that this continuous 
microfluidic separation system may be used as a preliminary module to a lab-on-chip system. 
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